Eating about one serving per day of green, leafy vegetables may be linked to a slower rate of brain aging, according to a study published in the December 20, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
While cognitive abilities naturally decline with age, eating one serving of leafy green vegetables a day may aid in preserving memory and thinking skills as a person grows older, according to a study by researchers at Rush University Medical Center in Chicago. The study results were published in the December 20, issue of Neurology, the medical journal of the American Academy of Neurology.
Dementia affects millions of people worldwide, robbing them of their ability to think, remember and live as they once did. In the search for new ways to fight cognitive decline, scientists report in ACS’ Journal of Agricultural and Food Chemistry that blueberry vinegar might offer some help. They found that the fermented product could restore cognitive function in mice.
In adults ages 60 and older, moderate daily walks improve attention and mental skills, study finds
From trial-ready registries to genotyping parties, the field has developed new techniques and meds to stem a tide of failed trials. Alzforum’s 13-part series sums up the state of the art as presented at a recent conference.
Canola oil is one of the most widely consumed vegetable oils in the world, yet surprisingly little is known about its effects on health.
Researchers from Case Western Reserve University School of Medicine have received two grant awards, in partnership with investigators from other institutions, from the National Institutes of Health to conduct major studies on Alzheimer’s disease, the most common form of memory loss and other forms of dementia in older persons.
Se espera que un nuevo consorcio de ensayos clínicos fundado por los Institutos Nacionales de Salud (NIH, por sus siglas en inglés) acelere los estudios y los amplíe a terapias para tratar o prevenir la enfermedad de Alzheimer y otras demencias afines.
ROCHESTER, Minn. — A new clinical trials consortium funded by the National Institutes of Health (NIH) is expected to accelerate and expand research into therapies that treat or prevent Alzheimer’s disease and related dementias.
Loneliness in older Americans is linked to serious medical conditions, including Alzheimer’s disease, stroke and heart disease as well as a higher risk of premature death. But loneliness can be easily overlooked as a health risk because healthcare providers can neglect asking their older patients about their social lives, and many older adults are too proud or embarrassed to ask for help, experts say. Cedars-Sinai geriatricians suggest tips for seniors who may feel especially isolated during the holidays.
This past decade, Alzheimer’s science has undergone a paradigm shift toward the disease’s early, silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
About 15 million Americans will have either Alzheimer’s dementia or mild cognitive impairment by 2060, up from approximately 6.08 million this year. The findings highlight the need to develop preventive measures that could slow the progression of the disease in at risk for Alzheimer’s dementia.
Summary: Playing 3D-platform video games on a regular basis may improve cognitive functions in seniors and increase grey matter in a brain structure called the hippocampus, a Canadian study suggests
People who carry the APOE4 genetic variant face a substantial risk for developing Alzheimer’s disease. Now, researchers at Washington University School of Medicine in St. Louis have identified a compound that targets the APOE protein in the brains of mice and protects against damage induced by the Alzheimer’s protein amyloid beta. The findings suggest that APOE could potentially be a target for treatment or prevention.
A new small-molecule drug can restore brain function and memory in a mouse model of Alzheimer’s disease. The molecule, called anle138b, works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envision that this drug could be used to treat Alzheimer’s and other neurodegenerative diseases such as Parkinson’s and ALS.
Making an AD mouse model that incorporates both Aβ and tau pathologies in a more AD-relevant context has been greatly sought after but difficult to accomplish. This study is a big step for AD research, which will allow testing of new therapies in a more realistic context.
Ludwig Cancer Research extends its warmest congratulations to Don Cleveland, who has been a Member of the Ludwig Institute for Cancer Research since 1995 and today was awarded the prestigious Breakthrough Prize.
Researchers will be using powerful lasers to look into the brains of animals to watch neurons firing as a way study the progression of neurodegenerative diseases.
The health advantages of high-intensity exercise are widely known but new research from McMaster University points to another major benefit: better memory. The findings could have implications for an aging population which is grappling with the growing problem of catastrophic diseases such as dementia and Alzheimer’s.
Researchers at Fresno State and CSU Fullerton are among those studying better ways to prevent the most common form of dementia.
Understanding how brains actively erase memories may open new understanding of memory loss and aging, and open the possibility of new treatments for neurodegenerative disease.
https://www.ncbi.nlm.nih.gov/pubmed/29078267
Aging research specialists have identified, for the first time, a form of mental exercise that can reduce the risk of dementia.
The American Heart Association (AHA) and Lawrence Livermore National Laboratory (LLNL) have formed a strategic business partnership to overcome the burden of drug discovery, cost and access.
University of Arkansas biomedical engineering doctoral student Asya Ozkizilcik has improved the nanowiring of drugs for an international team of researchers who are working on a new method for treating neurodegenerative diseases.
The number of older adults with Alzheimer’s disease continues to rise, but the number of treatments for the condition has not kept pace. Now, researchers at Albert Einstein College of Medicine, part of Montefiore, have received a $6.3 million grant from the National Institutes of Health (NIH) to identify networks of genes in healthy centenarians that protect them against dementia. The results could help identify new targets for drugs to treat Alzheimer’s.
Scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check. The study, published in Nature Communications, shows that membralin regulates the cell’s machinery for producing beta-amyloid (or amyloid beta, Aβ), the protein that causes neurons to die in Alzheimer’s disease.
Researchers at SBP have identified a peptide that could lead to the early detection of Alzheimer’s disease (AD). The discovery, published in Nature Communications, may also provide a means of homing drugs to diseased areas of the brain to treat AD, Parkinson’s disease, as well as glioblastoma, brain injuries and stroke.
Obstructive sleep apnea (OSA) may put elderly people at greater risk of developing Alzheimer’s disease (AD), according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
Research by a team of Vanderbilt University Medical Center scientists suggests that older people whose hearts pump less blood have blood flow reductions in the temporal lobe regions of the brain, where Alzheimer’s pathology first begins.
Rural counties continue to rank lowest among counties across the U.S., in terms of health outcomes. A group of national organizations including the Robert Wood Johnson Foundation and the National 4-H Council are leading the way to close the rural health gap.
Researchers have identified a new protective function for a brain protein genetically linked to Alzheimer’s. The findings, published in the Journal of Experimental Medicine, could inform novel treatment strategies to combat neurodegenerative diseases.
A popular drug commonly used to treat Alzheimer’s disease has shown promise in laboratory and clinical trials for treating patients with sickle cell disease (SCD). Researchers have found that the molecule memantine stabilizes the development, longevity and function of red blood cells and is well-tolerated by SCD patients. The findings will be presented at the APS Physiological and Pathophysiological Consequences of Sickle Cell Disease conference.
Researchers studying how animals respond to infections have found a new pathway that may help in tolerating stressors that damage proteins. Naming the pathway the Intracellular Pathogen Response, the scientists say it is a newly discovered way for animals to cope with certain types of stress and attacks, including heat shock.
The National Institutes of Health has awarded Albert Einstein College of Medicine nutrition scientist Yasmin Mossavar-Rahmani, Ph.D., R.D., a five-year, $4 million grant to test whether a diet rich in foods with anti-inflammatory properties can reduce cognitive decline and Alzheimer's disease risk. Middle-aged and older participants from the Bronx will follow this diet, which is designed to appeal to a multicultural population, and researchers will measure cognitive function over time to assess its impact.
Researchers studying a protein that causes a hereditary degenerative brain disease in humans have discovered that the human, mouse and hamster forms of the protein, which have nearly identical amino acid sequences, exhibit distinct three-dimensional structures at the atomic level.
The UCLA Alzheimer’s and Dementia Care Program has received The SCAN Foundation’s first Innovation in Health Care Award. This year’s award recognized “Outstanding Partnerships: Meaningful Achievements, Measurable Outcomes.”
UNC School of Medicine neuroscientists discover a long-distance brain circuit that controls the production of new neurons in the hippocampus. Research could have implications for understanding and treating many brain disorders, including epilepsy, schizophrenia, depression, and Alzheimer’s disease
Douglas Scharre, director of the division of Cognitive Neurology at the The Ohio State University Wexner Medical Center, talks about a test you can take to determine if you may have the early signs of demential or Alzheimer's. He also talks about how to approach family members, or loved ones, who are experiencing dementia or Alzheimer's. Free Test: http://sagetest.osu.edu
Maintaining positive, warm and trusting friendships might be the key to a slower decline in memory and cognitive functioning, according to a new Northwestern Medicine study.
The Focused Ultrasound Foundation has received a pledge of $10 million in unrestricted funds from an anonymous donor to be matched 1:1 by 2022. This pledge comes at a pivotal time for the Foundation and the focused ultrasound field.
Alzheimer's Drug Discovery Foundation Releases Comprehensive Survey of Clinical-Stage Alzheimer's Drugs
UCLA neuroscientists have discovered precisely where and how to electrically stimulate the human brain to enhance people’s recollection of distinct memories.
They don’t get pay, recognition, or much of a break. They spend hours a day helping someone who may not even recognize them anymore. Now, a new poll gives a glimpse into the lives of the spouses, grown children and other family members and friends who act as caregivers for up to five million Americans with dementia.
The size, shape and number of dendritic spines in the brain may play a major role in whether someone gets Alzheimer’s disease, according to new research from UAB. Findings showed healthy dendritic spines conveyed a protective effect against Alzheimer’s.
The Alzheimer's Association and Alzheimer's Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer's disease to be conducted by Amylyx Pharmaceuticals. The $1.85 million grant is the first award under an initiative created by the Alzheimer's Association and the ADDF to fund combination therapies.
With $3.8 million in support from the National Institute on Aging, University of California, Irvine neurobiologists are working to identify the early indicators of dementia in older adults as disease-related brain plaques accumulate but before symptoms can be observed.
Penn Medicine study illuminates how seniors cope with Alzheimer’s-risk biomarker results
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right